Neos Therapeutics Inc (NEOS) Stake Decreased by Falcon Point Capital LLC
Falcon Point Capital LLC cut its stake in shares of Neos Therapeutics Inc (NASDAQ:NEOS) by 44.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,530 shares of the company’s stock after selling 51,339 shares during the quarter. Falcon Point Capital LLC’s holdings in Neos Therapeutics were worth $658,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Essex Investment Management Co. LLC grew its stake in shares of Neos Therapeutics by 24.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 238,152 shares of the company’s stock worth $2,179,000 after purchasing an additional 46,423 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Neos Therapeutics by 103.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock worth $320,000 after purchasing an additional 22,200 shares during the period. Northern Trust Corp grew its stake in shares of Neos Therapeutics by 20.9% during the 2nd quarter. Northern Trust Corp now owns 201,266 shares of the company’s stock worth $1,470,000 after purchasing an additional 34,767 shares during the period. Citadel Advisors LLC acquired a new position in shares of Neos Therapeutics during the 3rd quarter worth $617,000. Finally, Vanguard Group Inc. grew its stake in shares of Neos Therapeutics by 25.7% during the 2nd quarter. Vanguard Group Inc. now owns 740,160 shares of the company’s stock worth $5,403,000 after purchasing an additional 151,166 shares during the period. 45.95% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently commented on NEOS shares. BMO Capital Markets cut shares of Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. Zacks Investment Research cut shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Cantor Fitzgerald set a $20.00 price objective on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 1st. BidaskClub raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Finally, Wells Fargo & Co set a $14.00 price objective on shares of Neos Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $14.00.
TRADEMARK VIOLATION NOTICE: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://theolympiareport.com/2018/02/14/neos-therapeutics-inc-neos-stake-decreased-by-falcon-point-capital-llc.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Want to see what other hedge funds are holding NEOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neos Therapeutics Inc (NASDAQ:NEOS).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.